RNAC Q2 2023 Earnings — Cartesian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

RNACCartesian Therapeutics, Inc.

$218M

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$5M-86.6% YoY

Gross Profit

-$13M-238.8% margin

Operating Income

-$19M-355.1% margin

Net Income

-$11M-216.9% margin

EPS (Diluted)

$-2.23

QoQ Revenue Growth

-11.6%

Cash Flow

Operating Cash Flow

-$10M

Free Cash Flow

-$10M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$140M

Total Liabilities

$74M

Stockholders' Equity

$65M

Cash & Equivalents

$112M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5M	$39M	-86.6%
Gross Profit	-$13M	$39M	-132.3%
Operating Income	-$19M	$14M	-234.5%
Net Income	-$11M	$9M	-232.4%